Table 2.
Outcomes by hydroxycarbamide exposure for hospitalization related to SCD
| Overall, No. (Column %) | HC exposed | HC not-exposed | p-value | High-dose HC *(≥1g/d) | Intermediate-dose HC (500mg-1g/d) | Low-dose HC Group (<500mg/d) | p-value | High adherent (PDC≥0.80) | Intermediate adherent (0.80>PDC≥0.50) | Non-adherent (PDC<0.50) | p-value | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitalizations, No. (%) | 20,721 | 4263 (20.6) | 16458 (79.4) | 793 (18.6) | 1354 (31.8) | 2116 (49.6) | 819 (19.2) | 1192 (28.0) | 2252 (52.8) | |||
| Primary outcomes | ||||||||||||
| SCD-related readmissions | ||||||||||||
| 7 day | 1318 (6.4) | 296 (6.9) | 1022 (6.2) | 0.0802 | 45 (5.7) | 81 (6.0) | 170 (8.0) | 0.0202 | 37 (4.5) | 66 (5.5) | 193 (8.6) | <.0001 |
| 30 day | 4076 (19.7) | 1034 (24.3) | 3042 (18.5) | <.0001 | 159 (20.1) | 295 (21.8) | 580 (27.4) | <.0001 | 140 (17.1) | 215 (18.0) | 679 (30.2) | <.0001 |
| All-cause readmission | ||||||||||||
| 7 day | 1436 (6.9) | 313 (7.3) | 1123 (6.8) | 0.2345 | 47 (5.9) | 86 (6.4) | 180 (8.5) | 0.0142 | 38 (4.6) | 69 (5.8) | 206 (9.1) | <.0001 |
| 30 day | 4527 (21.9) | 1103 (25.9) | 3424 (20.8) | <.0001 | 169 (21.3) | 315 (23.3) | 619 (29.3) | <.0001 | 152 (18.6) | 233 (19.5) | 718 (31.9) | <.0001 |
| All-cause acute care encounter | ||||||||||||
| 7 day | 2673 (12.9) | 555 (13.0) | 2118 (12.9) | 0.7947 | 72 (9.1) | 156 (11.5) | 327 (15.5) | <.0001 | 66 (8.1) | 125 (10.5) | 364 (16.2) | <.0001 |
| 30 day | 6762 (32.6) | 1583 (37.1) | 5179 (31.5) | <.0001 | 240 (30.3) | 455 (33.6) | 888 (42.0) | <.0001 | 216 (26.4) | 360 (30.2) | 1007 (44.7) | <.0001 |
| Secondary outcomes | ||||||||||||
| Length of stay (in days) | ||||||||||||
| median | 5 | 5 | 5 | <.0001 | 5 | 5 | 5 | 0.1217*** | 5 | 5 | 5 | <.0001*** |
| IQR | 3–7 | 3–8 | 3–7 | 3–8 | 3–7 | 3–8 | 3–7 | 3–7 | 4–8 | |||
| mean (SD) | 6.08 (5.65) | 6.19 (4.96) | 6.05 (5.81) | 0.1228 | 6.13 (5.55) | 6.13 (5.13) | 6.25 (4.61) | 0.7476 | 6.42 (4.74) | 6.21 (5.99) | 6.41 (4.74) | <.0001 |
| Died at discharge | 40 (0.2) ** | 9 (0.2) | 31 (0.2) | 0.7629 | 2 (0.3) | 4 (0.3) | 2 (0.1) | 0.2376**** | 3 (0.4) | 2 (0.2) | 4 (0.2) | 0.5592**** |
IQR, interquartile range
*
High-dose hydroxycarbamide exposure defined by the median of the cumulative hydroxycarbamide dose among the ever-exposed population. Set at 90g across age groups. Any patient with >90g cumulative dose over the 180 days preceding the index admission event is considered as high-dose hydroxycarbamide users.
**
A total of 1023 cases with missing discharge status
***
Kruskal-Wallis Test was used to assess the mean rank for the length of stay across exposed groups
****
A total of 221 cases with missing discharge status